Generic/Brand Dose, Strength & Indication/ Mechanisms Adverse/ Nursing Responsibilities Rationale Client Teaching

Name & Formulation (10%) of Action (10%) Side Effects (20%) (20%) (20%)
Classification Interaction
(10%) (15%)
Generic: Hepatitis B Indication: Body as a  Monitor  Elevated temperature is  Learn
Prophylaxsis:  A desire for Whole: Mild temperature. a sign of infection and potential
Adult: IM protection from local Some patients should be addressed adverse
HEPATITIS B Recombivax 1mL hepatitis B in tenderness develop a immediately at the reaction.
VACCINE (10 mcg) at 0, 1, at injection temperature emergency department.
people who have  Do not
(Recombinant) and 6 months; site, local elevation of
not been breast
Engerix-B 1mL (20 previously inflammatory 38.3° C (101° F)
feed
mcg) at 0, 1, and 6 reaction following
Brand: vaccinated while
months or 0, 1 ,2, (swelling, vaccination that
 A sexually active taking
and 12 months. heat, may last 1 or 2
lifestyle in redness, days this drug
RECOMBIVAX, people who are without
Child: IM induration,
ENGERIX-B not in a long- consulting
Recombivax 0.5 mL pain); fever,
(5mcg) at 0.1, and term, mutually  To make patient more
malaise, physician
6 months; Engerix- monogamous  Communicate or comfortable
Classification: fatigue,
B 0.5 mL (10 mcg) relationship (eg, headache, assure patient
at 0, 1, and 6 > 1 sex partner dizziness, that the pain
ANTIINFECTIVE;
months or 0, 1, 2, faintness, due to injection
VACCINE during the
and 12 months. leg cramps, is mild and
previous 6
myalgia, generally
months)
Dialysis and arthralgia. tolerable.
Immunodeficient  Need for
Patients: evaluation or GI: Nausea,
Adult: IM treatment of a vomiting,  For family to
Recombivax 2mL sexually diarrhea.  Immunization understand dosing
(20 mcg) at 0, 1, transmitted schedule to schedule and the health
and 6 months infection Skin: Rash, client worker to be assured
Engerix-B 2mL (40  Current or recent urticaria, (Vaccination completion of the
mcg) at 0, 1, and 6 use of illicit pruritus. requires three vaccination.
months or 0,1, 2, injection drugs IM injections at
and 12 months.  Sex between prescribed
 men intervals.)
 Employment in
which workers
may be exposed
to blood or other
potentially
 Administer
infectious body
dosage
fluids (eg, health
correctly.
care, custodial, (Vaccine must  To prevent side effects
or public safety be administered like pain and fever as
workers) intramuscularly. well as
 Diabetes in ) underdosing/overdosing
people < 60
years (as soon
as feasible after
diagnosis) and
sometimes in
those ≥ 60 years
(based on
shared clinical
decision-making
between clinician
and patient
regarding the
risk of becoming
infected, having
severe
consequences if
infected, and
having an
adequate
immune
response to
 vaccination)
 End-stage renal
disease (eg,
being treated
with
hemodialysis)
 HIV infection
 A chronic liver
disorder (eg,
people with
hepatitis C,
cirrhosis, fatty
liver disease,
alcohol-related
liver disease,
autoimmune
hepatitis, or
alanine
aminotransferase
[ALT] or
aspartate
aminotransferase
[AST] level
greater than
twice the upper
limit of normal)
 Pregnant women
if at risk of
infection or
severe outcome
resulting from
infection during
pregnancy
(Heplisav-B®
 not currently
recommended
due to lack of
safety data in
pregnant
women)

Mechanism of
Action:
Suspension of
inactivated and purified
hepatitis B surface
antigen (HBsAg)
derived from human
plasma of screened
asymptomatic HBsAg-
positive carriers of
hepatitis B virus.
Hepatitis B vaccine
recombinant is the first
vaccine produced by
gene splicing. No
human plasma is used
in its production.

________________________________________ ___________________________________
Patient Name and Signature Name and Signature
Clinical Instructor:
Student Note: Please provide additional sheet/s if necessary